<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), driven by translocation and overexpression of the c-MYC gene, is an aggressive, highly proliferative <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and novel therapeutic strategies are required to overcome drug resistance following conventional treatments </plain></SENT>
<SENT sid="1" pm="."><plain>The importance of the prosurvival BCL-2 family member BCL-X(L) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell survival suggests that antagonistic <z:chebi fb="0" ids="30153">BH3</z:chebi>-mimetic compounds may have therapeutic potential </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we show that treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines with <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 induces caspase-3/7 activation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> with varying potency </plain></SENT>
<SENT sid="3" pm="."><plain>Using selective inhibitors, we identify <z:chebi fb="0" ids="16749">phosphoinositide</z:chebi> 3-kinase (PI3K) as a proproliferative/survival pathway in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells and investigate the potential of combined pharmacologic inhibition of both the BCL-2 family and PI3K signaling pathway </plain></SENT>
<SENT sid="4" pm="."><plain>PI3K/AKT inhibition and <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 treatment induced synergistic caspase activation, augmented <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and rendered chemoresistant cells sensitive </plain></SENT>
<SENT sid="5" pm="."><plain>Targeting mTORC1/2 with PP242 was also effective, either as a monotherapy or, more generally, in combination with <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 </plain></SENT>
<SENT sid="6" pm="."><plain>The combined use of a dual specificity PI3K/mTOR inhibitor (PI 103) with <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 proved highly efficacious </plain></SENT>
<SENT sid="7" pm="."><plain>PI 103 treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells was associated with an increase in BIM/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>-1 expression ratios and loss of c-MYC expression </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, blocking c-MYC function using the inhibitor 10058-F4 also induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> synergistically with <z:chebi fb="5" ids="53329">ABT</z:chebi>-737, suggesting that maintenance of expression of BCL-2 family members and/or c-MYC by the PI3K/AKT/mTOR pathway could contribute to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell survival and resistance to <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 </plain></SENT>
<SENT sid="9" pm="."><plain>The combined use of <z:chebi fb="0" ids="30153">BH3</z:chebi> mimetics and selective mTORC1/2 inhibitors may therefore be a useful novel therapeutic approach for the treatment of B-cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, including chemoresistant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>